← Back to news
October 13, 2026
FTC and States Seek Contempt Ruling Against Martin Shkreli
- The FTC and seven states filed a contempt claim against Shkreli for violating a 2022 court order.
- Shkreli allegedly traded in at least 60 pharmaceutical stocks since his release from prison.
- The filing seeks to impose financial penalties and potential incarceration for future violations.
Read the news this way every day.
Concur organizes political reporting into clear stories and shows the sources behind each one.
Free. No ads.
3 Sources
- Martin Shkreli violated lifetime pharma industry ban, FTC and states say in contempt claimOct 13, 2026 at 1:22 PM · CNBC
- FTC: 'Pharma bro' Shkreli violated lifetime industry ban, should be held in contemptOct 13, 2026 at 5:05 PM · The Hill
- FTC, States Ask Court to Hold ‘Pharma Bro’ Shkreli in Contempt for Trading Drug StocksOct 13, 2026 at 8:15 PM · WSJ